Author

U. Banerji

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:cancer & tumor microenvironment· 1 Research Focus:drug response / drug discovery· 1 Organism:human· 1 Assay:scRNA-seq· 1

Frequent Co-Authors

A. A. Antolin· 1 shared A. Acar· 1 shared A. Sottoriva· 1 shared A. Stewart· 1 shared B. Al-Lazikani· 1 shared C. C. Maley· 1 shared D. Nichol· 1 shared G. D. Cresswell· 1 shared

Activity by Year

2019-2019 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperPharmacology & Toxicology

A. A. Antolin

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Exploiting evolutionary herding to control drug resistance in cancer

A. Acar, D. Nichol, J. Fernandez, G. D. Cresswell, I. Barozzi, S. P. Hong, I. Spiteri, M. Stubbs, R. Burke, A. Stewart, G. Vlachogiannis, C. C. Maley, L. Magnani, N. Valeri, U. Banerji, A. Sottoriva

This paper demonstrates evolutionary herding in non-small cell lung cancer to control drug resistance by shifting clonal composition and inducing collateral sensitivity.

bioRxiv · Mar 4, 2019 · PreprintCancer Biology

The off-target kinase landscape of clinical PARP inhibitors

A. A. Antolin, M. Ameratunga, U. Banerji, P. Clarke, P. Workman, B. Al-Lazikani

This study identifies the off-target kinase profiles of four FDA-approved PARP inhibitors, revealing unique polypharmacological effects with potential clinical implications.

bioRxiv · Jan 14, 2019Pharmacology & Toxicology